Dr. Shah on Toxicites Associated With CAR T-Cell Therapy

Bijal D. Shah, MD
Published: Thursday, Nov 09, 2017



Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.

Although the toxicities associated with with CAR T-cell therapy receive a lot of attention, it remains the most promising therapy for relapsed leukemia, says Shah.

Shah adds that is important to understand that these toxicities are manageable, and the risk of dying from them is extremely low.
 
SELECTED
LANGUAGE


Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.

Although the toxicities associated with with CAR T-cell therapy receive a lot of attention, it remains the most promising therapy for relapsed leukemia, says Shah.

Shah adds that is important to understand that these toxicities are manageable, and the risk of dying from them is extremely low.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x